Sinovac serum-free rabies vaccine meets non-inferiority criteria for seroconversion rates and geometric mean concentrationsTrial shows serum-free vaccine works as well as standard rabies shots

Human vaccines & immunotherapeutics Published August 13, 2026 Study authors: Jing Yulin, Chang Xiaoqiang, Jin Zhongqiang, Yang Fei, Cai Yanbei, Chen Kun, Liu Shuo, Huang Lin, Li… PubMed ↗ DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that Sinovac serum-free rabies vaccine met non-inferiority for seroconversion rates and GMC across both 4-dose and 5-dose schedules.

This Phase III randomized controlled trial enrolled 2000 healthy participants aged 10 to 60 years with baseline rabies virus neutralizing antibodies (RVNA) <0.5 IU/mL. The study compared Sinovac serum-free rabies vaccine, administered via either a 5-dose schedule (D0,3,7,14,28) or two 4-dose schedules (D0,3,7,14 or D0,3,7,28), against a licensed rabies vaccine following the 5-dose Essen schedule.

Primary outcomes included seroconversion rates (SCRs) and geometric mean concentrations (GMCs) on D14, with SCRs also assessed on D42. The Sinovac groups achieved 100% SCRs on D14, D28, and D42. GMC values on D14 were 34.71 IU/mL for 4-dose group 1, 36.36 IU/mL for 4-dose group 2, and 33.17 IU/mL for the 5-dose group. The control group had a GMC of 37.38 IU/mL on D14.

Secondary outcomes showed 100% seropositive rates at 3 months and >97% at 6 months for Sinovac groups. Safety data indicated that most adverse events were Grade 1, with no serious adverse events reported; tolerability was comparable across all study groups. The Sinovac vaccine met non-inferiority criteria for SCR and GMC under both 4-dose and 5-dose schedules.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in the availability of effective rabies vaccines, particularly following reports that some imported dogs may have potentially ineffective rabies vaccination. While previous reports highlighted the fatal risk of rabies from bat exposures and specific cases of human rabies in the United States, this study provides data on the non-inferiority of the Sinovac serum-free vaccine compared to licensed alternatives.

Rabies is a deadly disease, making it vital that vaccines are both effective and easy to produce. Researchers recently tested a serum-free version of the rabies vaccine to see if it could provide the same level of protection as the current standard. They compared two different dosing schedules against the traditional five-dose method.

The study included 2,000 healthy people who did not have existing antibodies against the virus. The results showed that the serum-free vaccine reached a 100% seroconversion rate—meaning it successfully triggered an immune response—at the 14, 28, and 42-day marks. This performance was comparable to the licensed vaccine used today.

Safety data also looked positive. Most side effects were mild, and no serious issues were reported during the six-month follow-up period. While the study confirms this new version is just as effective at building immunity, you should always talk to a healthcare provider about the best vaccination plan for your specific needs.

What this means for you:

The serum-free rabies vaccine provides similar protection and safety to current standard vaccines.

Common questions

Is the new serum-free vaccine safe to use?

Yes, the study reported that the serum-free vaccine was well tolerated. Most side effects were Grade 1, which means they were mild. No serious adverse events were reported during the six-month follow-up period.

How effective is it compared to current vaccines?

The serum-free vaccine met non-inferiority criteria. This means it was just as effective at creating an immune response (seroconversion) and maintaining antibody levels as the licensed vaccine currently used in standard schedules.

How many doses are needed for protection?

The study tested both a 4-dose schedule and a 5-dose schedule. Both versions of the serum-free vaccine achieved a 100% seroconversion rate by day 14, showing strong results regardless of the specific dosing plan.

Study Details

Study typeRct

EvidenceLevel 2

PublishedAug 2026

PMID42456561

View Original Abstract ↓

BACKGROUND: Rabies is a fatal zoonotic disease that can be effectively prevented through timely postexposure prophylaxis (PEP). Serum-free rabies vaccines may theoretically reduce risks associated with animal-derived components, and simplified PEP schedules may improve vaccination compliance and accessibility. This trial evaluated the immunogenicity and safety of Sinovac serum-free rabies vaccine administered using 5-dose and simplified 4-dose schedules. METHODS: A randomized, double-blind, active-controlled phase III clinical trial was conducted in 2000 healthy participants aged 10-60 years. Participants were randomized in a 1:1:1:1 ratio to receive Sinovac rabies vaccine according to the 5-dose Essen schedule on D0,3,7,14,28 (5-dose study group), two 4-dose schedules on D0,3,7,14 (4-dose study group 1) or D0,3,7,28 (4-dose study group 2), or a licensed rabies vaccine according to the 5-dose Essen schedule (5-dose control group). Primary endpoints were seroconversion rates (SCRs) and geometric mean concentrations (GMCs) on D14 and SCRs on D42 in susceptible participants with baseline rabies virus neutralizing antibodies (RVNA) <0.5 IU/mL. Secondary endpoints included SCR and GMC on D28, seropositive rates at 3 and 6 months, and safety through 6 months. RESULTS: In susceptible participants, SCRs reached 100% on D14, D28, and D42 in all groups. On D14, RVNA GMCs were 34.71, 36.36, 33.17, and 37.38 IU/mL in the two 4-dose study groups, 5-dose study group, and the control group, respectively. All three Sinovac vaccine groups met the prespecified non-inferiority criteria versus the control group for D14 and D42 SCRs and D14 GMCs. Seropositive rates remained 100% at 3 months and above 97% at 6 months in all Sinovac vaccine groups. Safety profiles were comparable across groups, and most adverse reactions were Grade 1, with no vaccine-related serious adverse events reported. CONCLUSIONS: Sinovac serum-free rabies vaccine induced rapid, robust, and persistent immune responses under both 5-dose and simplified 4-dose schedules, with a favorable safety profile.

Sinovac serum-free rabies vaccine meets non-inferiority criteria for seroconversion rates and geometric mean concentrationsTrial shows serum-free vaccine works as well as standard rabies shots

How this fits prior evidence

Common questions

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Sinovac serum-free rabies vaccine meets non-inferiority criteria for seroconversion rates and geometric mean concentrationsTrial shows serum-free vaccine works as well as standard rabies shots

How this fits prior evidence

Common questions

More on Rabies

Study Details

High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants

High-Dose Vitamin D May Reduce BPD in Preterm Infants

Clinical research that matters. Delivered to your inbox.

Related in Pediatrics

From Other Specialties